Available Until 10/18/2022

Pediatric Pharmacy Specialty Recertification Literature Study: Module 1A-B (Cert # L229114)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 03/16/2022
Content Release Date: 04/13/2022
Expiration Dates: 10/18/2022
Activity Type: Application-based
CE Credits: 10.00 contact hours (BPS and ACPE)
Activity Fee: $55 (ASHP member); $110 (non-member)

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice and includes a short video for enhanced learning and understanding. 

Module 1A: Hematology/Oncology: This module focuses on pediatric hematology and oncology issues such as febrile neutropenia, nodular desmoplastic medulloblastoma, nelarabine for acute lymphoblastic leukemia, high-risk neuroblastoma and guidelines for sickle cell disease.   

Module 1B: Neonate: This module focuses on neonatal issues such as aerosilized calfactant for respiratory distress, new approach to recognize impaired kidney function, opioid withdrawal syndrome and use of probiotics. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP professional development program for BCPPS recertification approved by the BPS. 

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification contact hours through the Board of Pharmacy Specialties (BPS).

Board certified pharmacists are eligible to receive up to 10 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete these assessments.

Learning Activity

ACPE Number

Contact Hours (ACPE and BPS)

Assessment Pass Point

Pediatric Pharmacy Literature Study Module 1A: Hematology/Oncology

0204-0000-22-942-H01-P

6.0

71%

Pediatric Pharmacy Literature Study Module 1B: Neonate

0204-0000-22-943-H01-P

4.0

75%

Pediatric Pharmacy  Literature Study Module 1A: Hematology/Oncology
ACPE Number:0204-0000-22-942-H01-P

This module focuses on pediatric hematology and oncology issues such as febrile neutropenia, nodular desmoplastic medulloblastoma, nelarabine for acute lymphoblastic leukemia, high-risk neuroblastoma and guidelines for sickle cell disease.  

Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv (2020) 4 (12): 2656–2701.
https://doi.org/10.1182/bloodadvances.2020001851

Learning Objectives:

  • Describe the American Society of Hematology (ASH) 2020 guidelines for the management of acute and chronic pain in patients with sickle cell disease (SCD).
  • Develop recommendations for managing acute and chronic pain in patients with sickle cell disease (SCD).
  • Identify limitations to the current ASH guidelines and opportunities for future research.

Avilés-Robles MJ, Reyes-López A, Otero-Mendoza FJ, et al. Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: A noninferiority multicenter randomized clinical trial. Pediatr Blood Cancer. 2020 Jun;67(6):e28251. doi: 10.1002/pbc.28251. Epub 2020 Mar 20. PMID: 32196898.

Learning Objectives:

  • Describe the study by Avilés-Robles and colleagues comparing early step-down to oral outpatient antimicrobial treatment with conventional inpatient intravenous antimicrobial treatment for pediatric cancer patients with low-risk febrile neutropenia.
  • Develop recommendations for the use of antimicrobial therapy for pediatric cancer patients with low-risk febrile neutropenia.

Dhall G, O'Neil SH, Ji L, et al. Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial. Neuro Oncol. 2020 Dec 18;22(12):1862-1872. doi: 10.1093/neuonc/noaa102. PMID: 32304218; PMCID: PMC7746930.

Learning Objectives:

  • Describe the ""Head Start"" III study by Dhall and colleagues of young children with medulloblastoma.
  • Develop recommendations for the treatment of young children with medulloblastoma.

Dunsmore KP, Winter SS, Devidas M, et al. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. doi: 10.1200/JCO.20.00256. Epub 2020 Aug 19. PMID: 32813610; PMCID: PMC7526719.

Learning Objectives:

  • Describe the Children’s Oncology Group trial AALL0434 by Dunsmore and colleagues of nelarabine in patients with newly-diagnosed T-cell acute lymphoblastic leukemia (T-ALL).
  • Develop recommendations for the use of nelarabine in patients with newly-diagnosed T-cell acute lymphoblastic leukemia (T-ALL).

Mora J, Castañeda A, Gorostegui M, et al. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission. Pediatr Blood Cancer. 2021 May 22:e29121. doi: 10.1002/pbc.29121. Epub ahead of print. PMID: 34022112.

Learning Objectives:

  • Describe the study by Mora and colleagues of naxitamab combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) as consolidation for patients with high-risk neuroblastoma in complete remission.
  • Develop recommendations for the use of naxitamab combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) as consolidation for patients with high-risk neuroblastoma in complete remission.

Pediatric Pharmacy Literature Study Module 1B: Neonate
ACPE Number:0204-0000-22-943-H01-P

This module focuses on neonatal issues such as aerosilized calfactant for respiratory distress, new approach to recognize impaired kidney function, opioid withdrawal syndrome and use of probiotics. 

Cummings JJ, Gerday E, Minton S, et al. Aerosolized calfactant for newborns with respiratory distress: a randomized trial. Pediatrics. 2020 Nov;146(5):e20193967. doi: 10.1542/peds.2019-3967. Epub 2020 Oct 15. PMID: 33060258.

Learning Objectives:

  • Describe the study by Cummings and colleagues of aerosolized calfactant in newborn infants with mild-to-moderate respiratory distress.
  • Develop recommendations for the use of aerosolized calfactant in newborn infants with mild-to-moderate respiratory distress.

Perazzo S, Revenis M, Massaro A, Short BL, Ray PE. A New Approach to Recognize Neonatal Impaired Kidney Function. Kidney Int Rep. 2020 Oct 3;5(12):2301-2312. doi: 10.1016/j.ekir.2020.09.043. PMID: 33305124; PMCID: PMC7710891.

Learning Objectives:

  • Describe the study by Perazzo and colleagues of a method for detecting impaired kidney function (IKF) in critically ill neonates.
  • Develop recommendations for the detection of impaired kidney function (IKF) in critically ill neonates.

Patrick SW, Barfield WD, Poindexter BB; COMMITTEE ON FETUS AND NEWBORN, COMMITTEE ON SUBSTANCE USE AND PREVENTION. Neonatal Opioid Withdrawal Syndrome. Pediatrics. 2020 Nov;146(5):e2020029074. doi: 10.1542/peds.2020-029074. PMID: 33106341.

Learning Objectives:

  • Describe the American Academy of Pediatrics (AAP) statement on neonatal opioid withdrawal syndrome (NOWS), including recent trends and the clinical presentation, assessment, and treatment of the syndrome.
  • Develop recommendations for the management of neonatal opioid withdrawal syndrome (NOWS).

Poindexter B; COMMITTEE ON FETUS AND NEWBORN. Use of Probiotics in Preterm Infants. Pediatrics. 2021 Jun;147(6):e2021051485. doi: 10.1542/peds.2021-051485. Epub 2021 May 24. PMID: 34031231.

Learning Objectives:

  • Describe the differences among commercially available probiotic preparations, regulatory standards governing their use in the United States, potential risks associated with the use of probiotics, and currently available evidence of their efficacy and safety for the prevention and treatment of necrotizing enterocolitis (NEC) and late-onset sepsis in preterm infants.
  • Develop recommendations for the use of probiotics in preterm infants.

Full Faculty Bios

Zanette Kanani Bradley, Pharm.D., BCOP
Pediatric Oncology Clinical Pharmacist
Children's Hospital Colorado
Aurora, Colorado 

Austyn Grim, Pharm.D., BCPPS
Clinical Pharmacy Specialist - Pediatric Oncology/BMT
Texas Children’s Hospital
Houston, Texas 

Nicole Palazzolo, Pharm.D., BCPPS
NICU Clinical Pharmacist
UVA Children's Hospital
Charlottesville, Virginia 

Kynlon Phillips, Pharm.D., BCOP, BCPS, CPP
Clinical Pharmacist Practitioner, UNC Pediatric Hematology/Oncology Clinic
101 Manning Drive, CB# 7600
Chapel Hill, North Carolina 

Ashley Sabus, Pharm.D., BCOP
Clinical Pharmacist – Ambulatory Neuro-Oncology/Hematology/Ancillary Services
Children’s Hospital Colorado
Aurora, Colorado

Pooja Shah, Pharm.D., BCPPS
Clinical Associate Professor, Ernest Mario School of Pharmacy
Rutgers University, The State University of New Jersey
Piscataway, New Jersey 

Content Matter Experts

Peter N. Johnson, Pharm.D., BCPPS, BCPS, FCCM, FPPAG
Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma 

Jamie L. Miller, Pharm.D., BCPPS, BCPS, FPPAG
Associate Professor
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma 

Jennifer Thackray, Pharm.D., BCPPS, BCPS
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York

Michelle C. Abalos, Pharm.D.
Susan R. Dombrowski, B.S.Pharm., M.S.

Hakeem  Abayomi, B.S., Pharm.D., BCPS, BCPPS, BCIDP
Renad Abu-Sawwa, Pharm.D. BCPPS
Leanna Barker, Pharm.D., BCPPS
Samantha Brokenshire, Pharm.D., BCPPS
Darrin Dillingham, Pharm.D.
Alexandra Fife, Pharm.D., BCPPS
Christina Hellauer, Pharm.D., BCPPS
Pui Man (Julia) Ho, Pharm.D., BCPPS
Melissa Hunt, Pharm.D., BCPPS
Holly Kaminski, B.S.Pharm, BCPS, BCPPS
Jin  Kim, Pharm.D., BCPPS
Kelly Kopec, Pharm.D.  BCPPS
Thomas Laudone, Pharm.D., BCPPS
Fangchen Lin, Pharm.D., BCPPS
Kristin Luckeroth, Pharm.D., BCPPS
Justin McCord, Pharm.D., BCPPS
Cody Moseman, Pharm.D., BCPPS
Erin Munsel, Pharm.D., BCPPS
Christian Nicolosi, Pharm.D., BCPPS
Lucas Orth, Pharm.D., BCPPS
Seema Patel, Pharm.D., BCPPS, APHa
Kevin Poel, Pharm.D., BCPPS
Tamara Potter, Pharm.D., BCPPS
Mike Raschka, Pharm.D., BCPPS
Anna Simmont, Pharm.D., BCPS, BCPPS
Lindsay Villalobos, Pharm.D., BCPPS
Marry Vuong, Pharm.D., BCPPS
Ryan Wozniewicz, Pharm.D., BCPPS

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  •          Complete the attestation statement
  •          Review all content
  •          Complete and pass the assessments
  •          Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

These activities were developed by ASHP.